Patent ID: 9005636
Filing Date: 2015-04-14
Classification: A61K,A61P

Abstract:
1. A tablet comprising: (a) a therapeutically effective amount of metformin or its pharmaceutically acceptable salts, (b) sustained release carriers, (c) therapeutically effective amount of rosuvastatin or its pharmaceutically acceptable salts and (d) excipients, wherein the sustained release carrier is selected from the group consisting of hydroxy propyl methyl cellulose, sodium carboxyl methyl cellulose, methyl cellulose, ethyl cellulose, hydroxy methyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy ethyl methyl cellulose, hydroxy ethyl ethyl cellulose, hydroxy propyl ethyl cellulose, alkyl hydroxy propyl methyl cellulose, polyethylene oxide, polyvinyl acetate, polyvinyl alcohol, povidone and its derivatives, corn starch, potato starch, pregelatinized starch and its derivatives, hydroxy ethyl starch, dextrin and its derivatives, dextran, maltodextrin, polydextrose, alginic acid or its derivatives, guar gum, locust bean gum, xanthan gum, cyclodextrin, arabia gum, gellan gum, karaya gum, casein, tara gum, tamarind gum, tragacanth gum, ghatti gum, gelatin, collagen, protamine, zein, carbomer, polyacrylamide, poly vinyl acetal diethyl amino acetate, glucomannan, glucosamine, arabinogalactan, furcelleran, pullulan, polyurethane, chitosan, chitin, agar, pectin and carrageenan, the tablet, wherein a weight ratio of (a) metformin or its pharmaceutically acceptable salts: (b) sustained release carriers: (c) rosuvastatin or its pharmaceutically acceptable salts: (d) excipients is 1:0.01˜5:0.001˜0.5:0.01˜5; metformin or its pharmaceutically acceptable salts shows sustained release patterns where it is constantly eluted in water or physiological pH dissolution medium; and rosuvastatin or its pharmaceutically acceptable salts shows immediate release or sustained release patterns where it is constantly eluted in water or physiological pH dissolution medium.